Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 143

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 143
---
 December 31, 2024. 

16.    Composition of Other Balance Sheet Items

The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):

Inventories, Net September 30,2025December 31,2024(unaudited)Raw materials$56,988 $11,127 Work in process33,407 26,725 Finished goods16,705 16,441 Total$107,100 $54,293 Inventories, net as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):Balance Sheet ClassificationSeptember 30, 2025December 31, 2024(unaudited)Current inventoryInventories, net$79,399 $54,293 Noncurrent inventoryOther Assets27,701 — Total $107,100 $54,293 

 Property and Equipment, Net 

33

September 30,2025December 31,2024(unaudited)Lab equipment and furniture$13,916 $13,370 Leasehold improvements14,024 14,023 Software883 883 Computer equipment1,264 1,112 Subtotal30,087 29,388 Less accumulated depreciation and amortization(19,460)(17,843)Property and equipment, net$10,627 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.5 million and $1.6 million for the three and nine months ended September 30, 2025 and $0.6 million and $1.8 million for the three and nine months ended September 30, 2024, respectively.

Accounts Payable and Accrued LiabilitiesSeptember 30,2025December 31,2024(unaudited)Accounts payable$8,177 $4,587 Accrued compensation, benefits, & related accruals35,297 21,225 Accrued sales & marketing14,838 11,007 Accrued manufacturing expenses13,099 11,652 Accrued R&D expenses9,109 5,898 Operating lease liabilities, current portion(1)10,790 6,889 Accrued royalties(2)3,868 8,105 Other accrued expenses13,435 6,989 Total$108,613 $76,352